
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed Inc. has demonstrated promising clinical data for its product candidate, Neflamapimod, particularly shown in the Phase 2b RewinD-LB trial, where a 32-week open-label extension yielded significant results reported in July 2025. The trial highlighted a substantial risk reduction of 64% (p=0.0001) among patients exhibiting minimal evidence of Alzheimer's disease co-pathology, suggesting a strong therapeutic potential for treating age-related neurologic disorders. Additionally, the contrast with placebo recipients, who experienced a mean increase in tau levels, further underscores the efficacy of Neflamapimod in improving synaptic functioning for affected patients.
Bears say
CervoMed Inc faces significant risks that contribute to a negative outlook on its stock, particularly related to its lead product candidate, Neflamapimod. Key concerns include the potential inability to establish an acceptable clinical development pathway for regulatory approval from the FDA, the prospect of generating non-positive data from pivotal trials, and the likelihood of slower market adoption post-approval. Furthermore, a discounted cash flow valuation methodology, which incorporates a 12% discount rate and a mere 40% probability of regulatory approval, highlights the financial uncertainty surrounding the company.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares